Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 304

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 304
---
 par value and per share amounts, unless otherwise noted)

During the six months ended December 31, 2023, the Company received stockholder approval to issue 20 % or more of its outstanding shares as of the date the Company entered into the Purchase Agreement with Lincoln Park. The Purchase Agreement may be terminated by the Company at any time, at its sole discretion, without any cost or penalty, by giving one business day notice to Lincoln Park to terminate the Purchase Agreement.

During the six months ended December 31, 2022, the Company sold 229 shares of common stock for total net proceeds of approximately $ 1,903 under this Purchase Agreement.

2017 Omnibus Incentive Plan

As subsequently approved by the Company’s stockholders at an annual meeting of stockholders, on April 11, 2018, the Company’s board of directors approved the adoption of the Company’s 2017 Omnibus Equity Incentive Plan (the “2017 Plan”), as amended. The board of directors also approved a form of Performance Stock Unit Award Agreement to be used in connection with grants of performance stock units (“PSUs”) as well as a Restricted Stock Unit (“RSU”) award under the 2017 Plan. As approved by the Company’s stockholders on June 21, 2022, the number of common shares available under the 2017 Plan as of December 31, 2023, is 440 shares, less the number of shares of common stock issued under the Del Mar (BC) 2013 Amended and Restated Stock Option Plan (the “Legacy Plan”), or that are subject to grants of stock options made, or that may be made, under the Legacy Plan, or that have been previously exercised.

The following table sets forth the aggregate information on all equity compensation plans as of December 31, 2023:

| Plan (in thousands, except pershare amounts)                                                                          |     | Number of shares ofcommon stock to beissued upon exercise ofoutstanding stock optionsand rights(a) |     |     | Weighted-averageexercise price ofstock options andrights$ |          |     | Number of shares of common stockremaining available for futureissuance under equity compensationplans (excluding securities reflectedin column (a))(2) |     |
| Equity compensation plans approved by security holders - 2017 Plan(1)                                                 |     |                                                                                                    | 236 |     |                                                           |    21.16 |     |                                                                                                                                                        | 129 |
| Equity compensation